Iambic and Takeda Strike $1.7B-Plus AI Drug Discovery Deal Targeting Oncology and GI Diseases
AI-first drug discovery continues to move from promise to production, and pharma partnerships are increasingly where that shift becomes real. Iambic, a clinical-stage life science and technology company focused on AI-driven drug discovery and development, today announced a multi-year technology and discovery collaboration with Takeda—one of the clearest signals yet that large pharmaceutical companies are betting on AI as core R&D infrastructure, not just an experimental add-on.
